17 January 2024
17 January 2024
There are several CRISPR therapies in Phase II and III trials which could be landmark approvals for their respective fields.
The Switzerland based company plans to use the Series B money to fund clinical trials for its three pipeline candidates.
Allakos’ stock price has plummeted following the announcement of two Phase II studies failing to meet their primary endpoints.
The double-blind, randomised, placebo-controlled study is designed to evaluate the safety and efficacy of HRO350.
The expression of beta-sarcoglycan 60 days following treatment with SRP-9003 is the trial’s primary endpoint.
AB126 demonstrates potential anti-inflammatory and neuroprotective effects.
The trial of ANAVEX 3-71 for schizophrenia is set to begin in the second quarter of this year.
As the deadline nears for the government to reveal its proposed prices, pharmaceutical companies are continuing to fight regulation.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
